| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 11.60B | — |
| Operating expense | — | — |
| Net income | 343.00M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, SNY returned -5.8% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -0.1% |
| 1 year | -5.8% |
| 5 years | +9.7% |
| 10 years | +79.6% |
| All-time high | $57.63 (Sep 2024) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in SNY would be worth today ›Yes. Sanofi paid 1 dividend over the past 12 months. The most recent was $2.42 per share on May 4, 2026. The dividend yield is 5.28%.
Sanofi stock trades on NASDAQ under the ticker symbol SNY.
Sanofi is part of the Healthcare sector.
Sanofi has a market cap of 109.86B USD, based on the latest quote.
Sanofi is scheduled to report earnings on Oct 30, 2026.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
